Argos Therapeutics (NASDAQ:ARGS): The mean short term price target for Argos Therapeutics (NASDAQ:ARGS) has been established at $12.8 per share. The higher price target estimate is at $18 and the lower price target estimate is expected at $10 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $3.27
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Roth Capital maintains its rating on Argos Therapeutics (NASDAQ:ARGS).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Roth Capital raises the new price target from $11 per share to $18 per share. The rating by the firm was issued on April 19, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Abbey Jeffrey D, CEO of Argos Therapeutics Inc had purchased 5,000 shares on December 14, 2015 in a transaction. The price per share was $2.5 and the total amount of the disclosed transaction was $12,500.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Argos Therapeutics (NASDAQ:ARGS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.46 points or 19.7% at $5.95 with 1,050,677 shares getting traded. Post opening the session at $7.9, the shares hit an intraday low of $5.9 and an intraday high of $7.9 and the price was in this range throughout the day. The company has a market cap of $154 million and the number of outstanding shares have been calculated to be 25,891,959 shares. The 52-week high of Argos Therapeutics (NASDAQ:ARGS) is $13.97 and the 52-week low is $1.61.
Argos Therapeutics, Inc. (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Companys advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. The Company is also developing AGS-004, its second Arcelis-based product candidate, for the treatment of Human Immunodeficiency Virus (HIV). The Company is conducting a Phase III clinical trial of AGS-003 plus sunitinib/targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA) with the Food and Drug Administration (FDA). The Company has completed three clinical trials of AGS-004. The Companys Arcelis technology platform utilizes biological components from a patients own cancer cells or virus to generate personalized immunotherapies.